Xvivo Perfusion AB (publ) (STO: XVIVO)
Sweden
· Delayed Price · Currency is SEK 533.00
+3.00 (0.57%)
Aug 30, 2024, 5:29 PM CET
Xvivo Perfusion AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 698.73 | 597.54 | 415.29 | 258.39 | 179.86 | 220.84 | Upgrade
|
| Revenue Growth (YoY) | 33.46% | 43.88% | 60.73% | 43.66% | -18.55% | 17.55% | Upgrade
|
| Cost of Revenue | 180.54 | 152.43 | 118.34 | 70.11 | 50.13 | 58.02 | Upgrade
|
| Gross Profit | 518.18 | 445.11 | 296.96 | 188.28 | 129.73 | 162.81 | Upgrade
|
| Selling, General & Admin | 342.06 | 309.21 | 223.38 | 153.38 | 107.71 | 85.53 | Upgrade
|
| Research & Development | 139.8 | 135.94 | 69.34 | 54.04 | 66.74 | 62.65 | Upgrade
|
| Other Operating Expenses | -6.48 | -5.43 | -0.22 | -0.39 | -0.53 | 3.62 | Upgrade
|
| Operating Expenses | 475.38 | 439.72 | 292.5 | 207.02 | 173.92 | 158.84 | Upgrade
|
| Operating Income | 42.81 | 5.4 | 4.45 | -18.74 | -44.19 | 3.97 | Upgrade
|
| Interest Expense | -1.19 | -1.19 | -0.61 | -0.28 | -0.36 | -0.29 | Upgrade
|
| Interest & Investment Income | 2.09 | 8.85 | 2.12 | - | 0.08 | 0.47 | Upgrade
|
| Currency Exchange Gain (Loss) | 9.69 | 9.69 | 17.09 | 5.98 | -12.6 | 1.26 | Upgrade
|
| Other Non Operating Income (Expenses) | 76.78 | 72.78 | -0.49 | 19.75 | -0.2 | -0.06 | Upgrade
|
| EBT Excluding Unusual Items | 130.17 | 95.52 | 22.58 | 6.71 | -57.26 | 5.35 | Upgrade
|
| Gain (Loss) on Sale of Assets | -1 | -1 | -0.26 | -0.04 | - | -0.06 | Upgrade
|
| Pretax Income | 129.17 | 94.52 | 22.31 | 6.67 | -57.26 | 5.29 | Upgrade
|
| Income Tax Expense | 8.43 | 2.7 | 3.89 | -1.49 | -13.53 | 0.35 | Upgrade
|
| Net Income | 120.74 | 91.82 | 18.43 | 8.15 | -43.74 | 4.94 | Upgrade
|
| Net Income to Common | 120.74 | 91.82 | 18.43 | 8.15 | -43.74 | 4.94 | Upgrade
|
| Net Income Growth | 343.98% | 398.29% | 126.04% | - | - | -61.06% | Upgrade
|
| Shares Outstanding (Basic) | 31 | 30 | 30 | 29 | 27 | 27 | Upgrade
|
| Shares Outstanding (Diluted) | 31 | 30 | 30 | 29 | 27 | 27 | Upgrade
|
| Shares Change (YoY) | 3.61% | 1.39% | 2.04% | 6.49% | 1.39% | 1.89% | Upgrade
|
| EPS (Basic) | 3.93 | 3.07 | 0.62 | 0.28 | -1.61 | 0.19 | Upgrade
|
| EPS (Diluted) | 3.93 | 3.07 | 0.62 | 0.28 | -1.61 | 0.18 | Upgrade
|
| EPS Growth | 330.03% | 394.73% | 121.43% | - | - | -62.50% | Upgrade
|
| Free Cash Flow | 5.78 | 3.27 | 9.67 | -22.25 | -14.9 | 19 | Upgrade
|
| Free Cash Flow Per Share | 0.19 | 0.11 | 0.33 | -0.77 | -0.55 | 0.71 | Upgrade
|
| Gross Margin | 74.16% | 74.49% | 71.51% | 72.87% | 72.13% | 73.73% | Upgrade
|
| Operating Margin | 6.13% | 0.90% | 1.07% | -7.25% | -24.57% | 1.80% | Upgrade
|
| Profit Margin | 17.28% | 15.37% | 4.44% | 3.15% | -24.32% | 2.24% | Upgrade
|
| Free Cash Flow Margin | 0.83% | 0.55% | 2.33% | -8.61% | -8.28% | 8.60% | Upgrade
|
| EBITDA | 64.86 | 19.03 | 13.3 | -11.7 | -36.61 | 11.74 | Upgrade
|
| EBITDA Margin | 9.28% | 3.19% | 3.20% | -4.53% | -20.35% | 5.32% | Upgrade
|
| D&A For EBITDA | 22.05 | 13.64 | 8.85 | 7.04 | 7.58 | 7.77 | Upgrade
|
| EBIT | 42.81 | 5.4 | 4.45 | -18.74 | -44.19 | 3.97 | Upgrade
|
| EBIT Margin | 6.13% | 0.90% | 1.07% | -7.25% | -24.57% | 1.80% | Upgrade
|
| Effective Tax Rate | 6.53% | 2.86% | 17.42% | - | - | 6.64% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.